Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Miyoshi

Showing results (101-110 of 152) with videos related to

Pageof 16
Sort By:
Plos One|August 19, 2015
A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)Hiroshi Nomoto, Hideaki Miyoshi, Tomoo Furumoto, et al.
Journal of Diabetes Investigation|May 21, 2014
Ovarian morphology and prevalence of polycystic ovary syndrome in Japanese women with type 1 diabetes mellitusArina Miyoshi, So Nagai, Masamitsu Takeda, et al.
Medicine|November 19, 2021
Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor: A case reportYuki Oe, Hiraku Kameda, Hiroshi Nomoto, et al.
The Journal of Clinical Investigation|June 3, 2011
The role of lipid droplets in metabolic disease in rodents and humansAndrew S Greenberg, Rosalind A Coleman, Fredric B Kraemer, et al.
Diabetes|February 20, 2021
Glucokinase Inactivation Paradoxically Ameliorates Glucose Intolerance by Increasing β-Cell Mass in <i>db/db</i> MiceKazuno Omori, Akinobu Nakamura, Hideaki Miyoshi, et al.
Journal of Diabetes Research|January 31, 2022
Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation StudyYuki Oe, Hiroshi Nomoto, Akinobu Nakamura, et al.
Endocrine Journal|November 3, 2017
Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled studyMayuko Oita, Hideaki Miyoshi, Kota Ono, et al.
BMJ Open|February 9, 2020
Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison studyReina Kameda, Hiroshi Nomoto, Kyu Yong Cho, et al.
Journal of Diabetes Investigation|May 17, 2021
Dipeptidyl peptidase-4 inhibitor might exacerbate Graves' disease: A multicenter observational case-control studyTomonori Sekizaki, Hiraku Kameda, Hiroshi Nomoto, et al.
Journal of Diabetes Investigation|August 5, 2018
Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trialTakahiro Takase, Akinobu Nakamura, Chiho Yamamoto, et al.
Pageof 16

Showing results (101-110 of 152) with videos related to

Sort By:
Pageof 16
Plos One|August 19, 2015
A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)Hiroshi Nomoto, Hideaki Miyoshi, Tomoo Furumoto, et al.
Journal of Diabetes Investigation|May 21, 2014
Ovarian morphology and prevalence of polycystic ovary syndrome in Japanese women with type 1 diabetes mellitusArina Miyoshi, So Nagai, Masamitsu Takeda, et al.
Medicine|November 19, 2021
Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor: A case reportYuki Oe, Hiraku Kameda, Hiroshi Nomoto, et al.
The Journal of Clinical Investigation|June 3, 2011
The role of lipid droplets in metabolic disease in rodents and humansAndrew S Greenberg, Rosalind A Coleman, Fredric B Kraemer, et al.
Diabetes|February 20, 2021
Glucokinase Inactivation Paradoxically Ameliorates Glucose Intolerance by Increasing β-Cell Mass in <i>db/db</i> MiceKazuno Omori, Akinobu Nakamura, Hideaki Miyoshi, et al.
Journal of Diabetes Research|January 31, 2022
Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation StudyYuki Oe, Hiroshi Nomoto, Akinobu Nakamura, et al.
Endocrine Journal|November 3, 2017
Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled studyMayuko Oita, Hideaki Miyoshi, Kota Ono, et al.
BMJ Open|February 9, 2020
Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison studyReina Kameda, Hiroshi Nomoto, Kyu Yong Cho, et al.
Journal of Diabetes Investigation|May 17, 2021
Dipeptidyl peptidase-4 inhibitor might exacerbate Graves' disease: A multicenter observational case-control studyTomonori Sekizaki, Hiraku Kameda, Hiroshi Nomoto, et al.
Journal of Diabetes Investigation|August 5, 2018
Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trialTakahiro Takase, Akinobu Nakamura, Chiho Yamamoto, et al.
Pageof 16